Verastem, Inc. (2VSA.F)
EUR 4.26
(0.47%)
EUR 4.26
(0.47%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -73.81 Million USD | -3.67% |
| 2021 | -71.2 Million USD | -5.13% |
| 2020 | -67.72 Million USD | 54.61% |
| 2019 | -149.2 Million USD | -105.99% |
| 2018 | -72.43 Million USD | -6.83% |
| 2017 | -67.8 Million USD | -86.06% |
| 2016 | -36.44 Million USD | 37.03% |
| 2015 | -57.86 Million USD | -8.43% |
| 2014 | -53.36 Million USD | -29.52% |
| 2013 | -41.2 Million USD | -28.82% |
| 2012 | -31.98 Million USD | -133.75% |
| 2011 | -13.68 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -8.25 Million USD | 75.62% |
| 2024 Q1 | -33.86 Million USD | -23.73% |
| 2023 Q3 | -20 Million USD | 17.61% |
| 2023 Q2 | -24.28 Million USD | -54.52% |
| 2023 Q1 | -15.71 Million USD | 6.51% |
| 2023 Q4 | -27.36 Million USD | -36.81% |
| 2022 Q1 | -16.96 Million USD | -2.92% |
| 2022 Q4 | -16.8 Million USD | 7.09% |
| 2022 Q3 | -18.09 Million USD | 17.59% |
| 2022 Q2 | -21.95 Million USD | -29.42% |
| 2022 FY | -73.81 Million USD | -3.67% |
| 2021 FY | -71.2 Million USD | -5.13% |
| 2021 Q2 | -16.9 Million USD | -12.45% |
| 2021 Q3 | -22.78 Million USD | -34.81% |
| 2021 Q4 | -16.48 Million USD | 27.67% |
| 2021 Q1 | -15.03 Million USD | 24.33% |
| 2020 Q3 | 13.13 Million USD | 157.1% |
| 2020 Q4 | -19.86 Million USD | -251.2% |
| 2020 Q2 | -23.01 Million USD | 39.43% |
| 2020 Q1 | -37.99 Million USD | 2.02% |
| 2020 FY | -67.72 Million USD | 54.61% |
| 2019 Q1 | -38.1 Million USD | -235.73% |
| 2019 Q2 | -42.19 Million USD | -10.74% |
| 2019 Q3 | -30.13 Million USD | 28.57% |
| 2019 FY | -149.2 Million USD | -105.99% |
| 2019 Q4 | -38.77 Million USD | -28.65% |
| 2018 FY | -72.43 Million USD | -6.83% |
| 2018 Q4 | -11.34 Million USD | 47.62% |
| 2018 Q2 | -18.36 Million USD | 12.75% |
| 2018 Q3 | -21.66 Million USD | -17.97% |
| 2018 Q1 | -21.05 Million USD | -15.44% |
| 2017 Q4 | -18.23 Million USD | 21.15% |
| 2017 FY | -67.8 Million USD | -86.06% |
| 2017 Q3 | -23.12 Million USD | -72.12% |
| 2017 Q2 | -13.43 Million USD | -3.31% |
| 2017 Q1 | -13 Million USD | -11.58% |
| 2016 Q4 | -11.65 Million USD | -47.12% |
| 2016 Q3 | -7.92 Million USD | 7.55% |
| 2016 Q1 | -8.29 Million USD | 30.09% |
| 2016 Q2 | -8.56 Million USD | -3.32% |
| 2016 FY | -36.44 Million USD | 37.03% |
| 2015 Q3 | -15.44 Million USD | -0.44% |
| 2015 Q4 | -11.86 Million USD | 23.19% |
| 2015 Q2 | -15.37 Million USD | -1.3% |
| 2015 Q1 | -15.18 Million USD | -8.83% |
| 2015 FY | -57.86 Million USD | -8.43% |
| 2014 Q3 | -13.33 Million USD | -2.38% |
| 2014 Q4 | -13.94 Million USD | -4.63% |
| 2014 Q1 | -13.06 Million USD | -15.35% |
| 2014 Q2 | -13.02 Million USD | 0.31% |
| 2014 FY | -53.36 Million USD | -29.52% |
| 2013 Q2 | -10.25 Million USD | -13.42% |
| 2013 Q1 | -9.03 Million USD | -14.09% |
| 2013 FY | -41.2 Million USD | -28.82% |
| 2013 Q4 | -11.32 Million USD | -6.92% |
| 2013 Q3 | -10.59 Million USD | -3.33% |
| 2012 Q1 | -6.87 Million USD | -14.42% |
| 2012 Q2 | -6.82 Million USD | 0.67% |
| 2012 Q3 | -10.36 Million USD | -51.9% |
| 2012 FY | -31.98 Million USD | -133.75% |
| 2012 Q4 | -7.92 Million USD | 23.59% |
| 2011 Q4 | -6 Million USD | -48.38% |
| 2011 Q3 | -4.04 Million USD | -62.86% |
| 2011 FY | -13.68 Million USD | 0.0% |
| 2011 Q2 | -2.48 Million USD | -116.84% |
| 2011 Q1 | -1.14 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| BioNTech SE | 930.3 Million EUR | 107.934% |
| CureVac N.V. | -260.16 Million EUR | 71.629% |
| Biotest Aktiengesellschaft | 127 Million EUR | 158.12% |
| Biotest Aktiengesellschaft | 127 Million EUR | 158.12% |
| BRAIN Biotech AG | -8.27 Million EUR | -791.557% |
| Formycon AG | 75.79 Million EUR | 197.384% |
| Heidelberg Pharma AG | -20.34 Million EUR | -262.775% |
| Medigene AG | -16.17 Million EUR | -356.277% |